Finance

Lists
Why is CGON up 2,64%?
Dive Deeper
CGON:NASDAQ
CG Oncology Inc
64,93 $
+2,64%
(+1,67) 1D
9 հոկ, 13:03:53 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGON...
Open
62,97 $
High
65,18 $
Low
62,88 $
Mkt. cap
5,76 մլրդ
Avg. vol.
931,12 հզր
Volume
153,96 հզր
52-wk high
80,97 $
52-wk low
35,80 $
EPS
-2,70 $
Shares outstanding
88,64 մլն
No. of employees
142
Open
62,97 $
High
65,18 $
Low
62,88 $
Mkt. cap
5,76 մլրդ
Avg. vol.
931,12 հզր
Volume
153,96 հզր
52-wk high
80,97 $
52-wk low
35,80 $
EPS
-2,70 $
Shares outstanding
88,64 մլն
No. of employees
142
News stories
From web sources and news partners
About CG Oncology Inc
CEO-
Employees142
Founded2010
HeadquartersԴալաս, Տեխաս, Միացյալ Նահանգներ
Sector-
Analyst ratings
Based on 10 analysts giving stock ratings to CGON in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for CGON in the last 3 months.
Highest
Current 64,93 $
108,00 $ (+66,33%)
Average
92,56 $ (+42,55%)
Lowest
79,00 $ (+21,67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gregory Renza
Truist Financial
Buy
Maintained
-
-
09/10/2026
David Dai
UBS
Buy
Reiterated
90,00 $
+38,6%
08/21/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
93,00 $
+43,2%
08/17/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
108,00 $
+66,3%
08/07/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
105,00 $
+61,7%
08/06/2026
Kelsey Goodwin
Piper Sandler
Buy
Reiterated
85,00 $
+30,9%
08/07/2026
Leonid Timashev
RBC Capital
Buy
Maintained
79,00 $
+21,7%
08/06/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
88,00 $
+35,5%
08/07/2026
Boris Peaker
JonesTrading
Buy
Maintained
85,00 $
+30,9%
08/06/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
100,00 $
+54%
08/07/2026
Kalpit Patel
Wolfe Research
Hold
Maintained
-
-
05/26/2026
Robert Driscoll
Wedbush
Buy
Reiterated
80,00 $
+23,2%
05/18/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
96,00 $
+47,9%
05/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Soumit Roy
JonesTrading
Buy
Maintained
85,00 $
+30,9%
04/06/2026
Bradley Canino
Guggenheim
Buy
Reiterated
90,00 $
+38,6%
02/27/2026
Last report
06 օգս, 2026 թ.
Fiscal period
Q2 2026
-0,90 $ / -0,64 $
-40,06%miss
Revenue / Est. (USD)
1,16 մլն / 362,64 հզր
+219,05%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
1,67 մլն
2,32 մլն
1,08 մլն
1,16 մլն
Cost of goods sold
29,46 մլն
33,03 մլն
46,69 մլն
58,58 մլն
Cost of revenue
29,46 մլն
33,03 մլն
46,69 մլն
58,58 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23,33 մլն
17,99 մլն
20,78 մլն
28,98 մլն
Operating expense
23,33 մլն
17,99 մլն
20,78 մլն
28,98 մլն
Total operating expenses
52,80 մլն
51,02 մլն
67,47 մլն
87,56 մլն
Operating income
-51,13 մլն
-48,70 մլն
-66,39 մլն
-86,40 մլն
Other non operating income
-100,00 հզր
-53,00 հզր
-101,00 հզր
16,00 հզր
EBT including unusual items
-43,81 մլն
-41,31 մլն
-60,20 մլն
-79,06 մլն
EBT excluding unusual items
-43,81 մլն
-41,31 մլն
-60,20 մլն
-79,06 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-43,81 մլն
-41,31 մլն
-60,20 մլն
-79,06 մլն
Net profit margin
-2 629,53%
-1 779,03%
-5 558,82%
-6 832,84%
Earnings per share
-0,57
-0,51
-0,71
-0,90
Interest and investment income
7,42 մլն
7,44 մլն
6,29 մլն
7,33 մլն
Interest expense
-
-
-
-
Net interest expenses
7,42 մլն
7,44 մլն
6,29 մլն
7,33 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-50,71 մլն
-47,85 մլն
-65,55 մլն
-85,55 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps